

#### American Association of Clinical Endocrinology



February 1, 2024

The Honorable Chiquita Brooks-LaSure Administrator Centers for Medicare & Medicaid Services Department of Health and Human Services 7500 Security Boulevard Baltimore, MD 21244-1850

Submitted electronically to MedicarePhysicianFeeSchedule@cms.hhs.gov

#### **RE:** Nomination as potentially misvalued codes during CY2025 rulemaking:

Fine Needle Aspiration - CPT codes 10021, 10004, 10005, 10006

Dear Administrator Brooks-LaSure:

The American Association of Clinical Endocrinology and the American Thyroid Association appreciate the opportunity to request nomination of the Fine Needle Aspiration codes as potentially misvalued.

We strongly feel that since these codes were redefined for CY 2019, that they were severely undervalued, and we are now presenting new evidence for your consideration. We urge CMS to restore the RVU values for these codes to the amounts recommended by the AMA – RUC for 2019.

#### I. Who we are:

AACE represents more than 5700 clinical endocrinologists who participate in Medicare, Medicaid, and commercial insurance plans. These clinicians work in private practice, academic practices, and health systems across the nation. We work to improve quality of endocrine care for patients and reduce health care cost. Our mission is *elevating the practice of clinical endocrinology to improve global health*. Our vision is *achieving healthier communities through endocrine innovation, education, and care*. The American Thyroid Association (ATA) is dedicated to transforming thyroid care through clinical excellence, education, scientific discovery, and advocacy in a collaborative and diverse community. ATA is an international professional medical society with more than 1,700 members from private practice, academic health centers and other practice and research settings globally.

#### **II.** Fine Needle Aspiration Procedures

Fine Needle Aspiration is the primary tool for evaluating thyroid nodules that are suspicious for thyroid cancer. When properly used, it avoids the need for thyroid surgery, which is far more invasive and expensive.

We have become increasingly alarmed about the negative impacts of the reduction of RVU for the "Fine Needle Aspiration" CPT code set 10005, 10006 and 10021 that began with the 2019 Physician Fee Schedule, and we ask that CMS review its previous decision to reduce payment for these codes now that we have further experience with the new valuation.

The specific codes in question are:

10021 - Fine Needle Aspiration without guidance , first lesion

10004 - Fine Needle Aspiration without guidance , first lesion

10005 Fine Needle aspiration biopsy, including ultrasound guidance first lesion

10006 Fine Needle aspiration biopsy with imaging guidance, each additional lesion

While the FNA procedure can be performed on many sites, 73.9% of the claims for CPT 10005 in 2022 were for thyroid, and 85.5% of claims for 10006 were for thyroid, making this predominantly a thyroid procedure.

The reduction in RVU for these procedures has resulted in reduced access to thyroid FNA procedures as many outpatient thyroid physician offices discontinue them altogether. This has caused a shift in the procedures to the hospital-based radiology locations resulting in a net increase in cost to Medicare. In 2022, the Place of Service continued to shift away from the lower cost Physician Office (non-facility) at 43.5% to Outpatient Hospital (On Campus) at 50%.

Hospital-based radiology locations are typically less focused on the optimal care of thyroid nodules, and the procedures are often performed by radiology Physician Assistants without comprehensive training in thyroid nodule assessment that is typically seen in endocrinology or thyroid specialist offices.

Finally, we have convincing evidence that new endocrinologists and thyroid specialists in training are being discouraged from learning the FNA procedure in fellowship because of the widespread sentiment by thyroid specialists that this procedure is so badly undervalued that it is no longer worthwhile to perform in a clinic setting. Most new endocrine and thyroid fellows no longer plan to perform this procedure after beginning their practice. This will further reduce access to this necessary procedure at the lowest cost place of service.

This is truly regrettable because we feel strongly that physicians specializing in thyroid disease provide the most cost-efficient way to evaluate thyroid nodules, can perform fine needle aspiration sampling with the lowest rate of complications and have the best insight about which nodules need to be sampled versus which thyroid nodules can be simply observed.

At the time of the CY2021 PFS Final Rule, CMS stated "In the event that there is a new review of these services, as opposed to a reaffirmation of the previous review, we would look forward to receiving any additional information or new data."

We are providing additional information and new data on the actual utilization of these codes since the change in RVU.

#### III. ORIGIN OF THE RVU PROBLEM

CPT Code 10021 for Fine Needle Aspiration was identified as part of the CMS OPPS/ASC cap payment proposal for CY2014, which intended to limit the practice expense (PE) payment in the PFS to the lower of either OPPS or ASC payment schedules. Although the OPPS/ASC cap proposal was not implemented in the final CY2014 rule, AMA RUC forwarded practice expense only recommendations to CMS for CY 2015. In the CY2016 Final Rule, CMS noted concern about implementing PE inputs without the corresponding physician work being reviewed.

Due to the need for clarifying language regarding the number of needle passes per lesion, and the realization that more than 75% of the procedures included ultrasound guidance for needle placement, the AMA RUC referred this concern to the AMA CPT Editorial panel for clarification.

For CPT 2019, the CPT Editorial Panel deleted CPT code 10022, revised CPT code 10021, and created nine new codes. Under the previous code structure, reporting FNA under image guidance with a certain modality for a single lesion would involve reporting deleted code 10022 and the corresponding image guidance code; under the current code structure only the new FNA code with bundled image guidance would be reported. FNA is most commonly performed under ultrasound guidance and uses the code 10005 for the first nodule sampled, and 10006 for any additional nodules.

The AMA RUC provided an assessment of the physician time and work involved and recommended an overall reduction in work value compared to previous years' codes.

CPT Code	Work RVU	Pre Time	Intra Time	Post Time	IWPUT
10021 (2018)	1.27	21	17	10	0.339
10021 RUC Recommended	1.20	10	15	8	0.53
10021 CMS Adopted	1.03	10	15	8	0.42
10005 (2018 Equivalent)					
10005 (RUC Recommended)	1.63	10	20	9	0.60
10005 (CMS Adopted)	1.46	10	20	9	0.52

#### **IV – FURTHER REDUCTIONS TAKEN BY CMS**

Despite the RVU reduction proposed by the AMA RUC, CMS further reduced the RVU in the CY2019 PFS. The primary procedure, 10005 was reduced from the RUC recommended 1.63 to the CMS adopted value of 1.46.

In the CY 2019 Final Rule, CMS stated "... that the recommended work pool is increasing by approximately 20 percent for the Fine Needle Aspiration family as a whole, while the recommended work time pool for the same codes is only increasing by about 2 percent."

It initially appeared to AMA, and to us, that the work pool comparisons used with the AMA RUC recommended RVU overcounted the expected RVU by exactly double. In discussions with CMS in January 2024, we are assured that this was not the case, and this did not drive any reduction in RVU for the procedure.

Unfortunately, as can be clearly seen in the below excerpt from table 12 from the CY 2019 Final Rule, CMS utilization crosswalk numbers don't add up, and the table itself appears to be in error. The source utilization for the two existing FNA codes 10021 and deleted code 10022 of a collective volume of 210,210, was greatly exceeded by the utilization destination column for 10021, 10004-10012 of a collective volume of 400,450. Those two numbers should have instead both totaled to an identical number, 210,210. CMS' destination utilization for code 10005 alone was erroneously higher than the source utilization for deleted code 10022 *Fine needle aspiration biopsy, with image guidance*.

#### Table Excerpt from CY 2019 Medicare Physician Fee Schedule Final Rule:

HCPCS code	Utilization source	Utilization destination	Work RVU source	Work pool source	Work RVU destination	Work pool destination	Work pool RVU change	Work pool % change
10021	23,755	21,380	1.27	30,169	1.20	25,655	-4,513	- 15
10004	0	2,376	0.00	0	0.80	1,900	1,900	
10005	0	270,753	0.00	0	1.63	441,327	441,327	
10006	0	30,621	0.00	0	1.00	30,621	30,621	
10007	0	6.857	0.00	0	1.81	12,411	12,411	
10008	0	873	0.00	0	1.18	1,030	1,030	
10009	0	60.665	0.00	0	2.43	147,416	147,416	
10010	0	6.831	0.00	0	1.65	11,271	11,271	
10011	0	83	0.00	0	C	0	0	
10012	0	3	0.00	0	C	0	0	
10022	186,455	0	1.27	236,798	0.00	0	-236,798	- 100

#### TABLE 12-FINE NEEDLE ASPIRATION WORK POOL COMPARISON

It is now our understanding that while the Table 12 may have contained errors, these numbers were not the basis for any CMS decision to lower the RVU.

The CY2019 PFS Final Rule stated "... that the recommended work pool is increasing by approximately 20 percent for the Fine Needle Aspiration family as a whole, while the recommended work time pool for the same codes is only increasing by about 2 percent."

We presume that this reflected a real concern that the Physician Work RVU was increasing from the 1.27 from the 2018 CPT codes to the higher value of 1.63 recommended by RUC despite a drop in service time.

#### V - REASSESSMENT OF RVU WORK CHANGES USING 2022 CLAIMS DATA

Neither the CY2019 Table 12, or the accompanying commentary in the CY2019 Final Rule, addresses the fact that the new CPT 10005 bundled the prior CPT codes 10022 and 76942, which had a combined work RVU of 1.94, and RUC was revaluing this combined code 10005 at 1.63.

CY2019 Table 12 does not include the Work RVU for any of the source imaging procedures bundled into the new codes, regardless of whether there is overcounting or not.

We respectfully submit for your consideration revised tables, using actual 2022 claims data, on the impact of the revised RVU. This utilization crosswalk includes the RVU for both components of the new CPT 10005 (previously 10022 plus 76942) as source RVU, and the fact that the source CPT 10022 would be billed multiple times for any additional nodules. These revised tables are included as an appendix.

Looking at the entire FNA family of CPT codes, these show a reduction in Work RVU Pool of 15.9% if the AMA RUC numbers had been adopted, and a reduction in Work RVU Pool of 23.8% based on the actual CMS RVU used today.

This is in stark contrast to the assessment that the "recommended work pool is increasing by 20%" found in the CY2019 PFS final rule. (See Attachments 1, 2 and 3.)

#### VI - TIME AND INTENSITY OF THIS SERVICE

CMS stated in the 2021 Physician Fee Schedule final rule that the utilization crosswalk was not the principal reason CMS rejected the RUC recommendations, but that it was due to the interservice time measurement. CMS chose to compare the high work intensity Fine Needle Aspiration codes (which are performed hundreds of thousands of times per year) to an obscure low intensity neonatal transfusion code which has limited time measurement data and is rarely billed to Medicare.

At the time of the CMS RVU decision, CMS identified the neonatal transfusion code (36440) as being a comparable code, based on the exact match in service times.

This was a very poor choice crosswalk for several reasons.

a. CPT 36440 is rarely used code, that is almost never billed to Medicare.

Claims for CPT 36440	
2015	0
2016	0
2017	0
2018	0
2019	1
2020	1
2021	0
2022	0

There are literally 2 claims in the last 8 years.

b. CPT 36440 is a pediatric procedure done on neonates. CPT 10021 is never done on neonates. This is a dissimilar code as far as the physicians who perform the code, and the patients having the procedure.

c. The training and experience level needed to properly perform these procedures significantly differs. A neonatal transfusion could be performed by an intern or resident in the neonatal ICU. Thyroid fine needle aspiration is learned at the endocrinology fellowship level of training, or as a surgery, otolaryngology, or radiology senior resident.

d. The work intensity is vastly different. The neck around the thyroid is filled with other structures including arteries, veins, nerves, muscles, esophagus, and trachea that complicate the procedure.

e. CPT 36440 is facility only, does not require any clinical staff pre-service time, and has no associated practice expense inputs.

Fine needle aspiration is a much more complex and potentially hazardous procedure. The thyroid has the carotid artery, jugular view, lymphatics, nerves, trachea, and the esophagus

in contact with the thyroid. The nodules that are sampled are commonly touching the carotid artery, jugular vein, or both. A deviation of only 1 - 2 millimeters can be disastrous if these blood vessels or other structures are accidentally punctured. The thyroid can be moving due to respiratory disease, patient swallowing, or patient anxiety.

There is significant physician work and a high level of clinical expertise necessary to select the proper nodules for sampling and to pre-plan the needle path. True competence requires significant training and a relatively high number of procedures. None of this exists with neonatal phlebotomy.



The AMA RUC used similar intensity procedures to calculate its RVU recommendation.

70470 (CT head or brain)	1.27	5	15	5	.0697
99283 (ER visit)	1.34	5	18	7	.0595
40490 (lip biopsy)	1.22	14	15	5	.0577
78451 (myocardial imaging)	1.38	10	15	5	.0621
95865 (needle EMG larynx)	1.57	10	15	7	.080
53855 (urethral stent insertion)	1.64	7	15	10	.0839

### VI. UNEXPECTED CHANGES SINCE THE IMPLEMENTATION OF THE NEW RVU

Despite vigorous objections by the impacted specialty groups, CMS implemented the lower RVU value.

We now present evidence as to the damage done to patient access, increasing overall costs, and degrading the physician workforce capable of competently performing this procedure.

#### VII. CONCERNS REGARDING PATIENT ACCESS SINCE IMPLEMENTATION

Actual claims filed for CPT 10005 have decreased since 2018. Claims for thyroid FNA have fallen 18% below CMS projections, suggesting that this is creating an access problem for correct diagnosis of thyroid cancer. Thyroid nodules increase with age, and with the increasing Medicare population is implausible that the number of suspicious thyroid nodules has decreased, or that the number of thyroid cancers has decreased.

Given that FNA is for diagnosis of thyroid cancer, a significant reduction in thyroid FNA would be expected to cause an increase in diagnosis of thyroid cancer at later and more advanced stages. This delay in treatment will cause increased morbidity, mortality, and costs.

### VIII. SHIFT FROM OUTPATIENT TO FACILITY LOCATIONS AND INCREASED COST TO MEDICARE

In 2018, the most common single location for a thyroid FNA was the physician office setting, with 47.1% of claims for CPT 10022. Claims for the multiple POS that include hospital facilities amounted to 52.06% of claims. By 2021, the hospital facility claims had increased to 55.08% of claims for the RVU family.

The reduction in payment for the FNA code family has caused non-facility outpatient practices to discontinue the procedure. From an economic perspective, one might think that a switch to a lower cost location makes sense. However, in this case the procedure is now being performed in a *vastly more expensive* location costing 524% more.

CPT Code	MPFS	National Total Non- y Payment	Total	and the second se	OPPS Facility	Payme Hospit	nt when in al Outpatient 5 (MPFS +	Site of Service % Differential (Hosptial Outpatient v Non-Facility)
Office	\$	137.92				\$	137.92	
Facility			\$ 73.87	\$	648.97	\$	722.84	524

If we consider the shift in location from Office to Facility that was seen between 2018 and 2021, with the additional cost of \$584.92 at the Facility location, Medicare experienced an additional cost of \$ 2,725,544 due to physicians in non-facility locations abandoning the procedure.

These calculations do not include any consideration of medically unnecessary FNA performed due to increasing referral to radiologists vs thyroid clinicians. We find that experienced thyroid clinicians are more likely to cancel a medically unnecessary FNA when they encounter a request that does not meet current FNA guidelines.

#### IX. SHIFT IN SPECIALTY PERFORMING THE SERVICE

Most endocrinologists are in office-based practices and not facilities. As they increasingly stop offering this procedure in their offices, the patients are referred to hospital-based radiology practices which are staffed by radiologists.

Reviewing the 2022 Medicare claims data, Radiologists now perform this procedure 52.3% of the time, with endocrinologists performing only 17.6% of the fine needle aspirations.

While radiologists are generally excellent at the technical components of this, there are several concerns about this additional referral. The radiology provider who performs this procedure is generally not familiar with the patient's history and risk factors for suspected thyroid cancer. Their training in thyroid cancer is more focused on the imaging and the procedure, and not viewing the problem from a whole patient point of view. Endocrinologists and surgeons have much more extensive clinical insight about the presentation, diagnosis, and treatment of thyroid nodules and thyroid cancer than radiologists. Many of these referrals for FNA come from Primary Care Providers who are not as experienced with this disease state and then referred to generalist radiologists who are less experienced with this disease state.

A significant number of thyroid FNA requests that come to endocrinologists and thyroid surgeons are found to not meet the clinical criteria for the procedure, and thus the procedure is canceled. It is uncommon for radiology providers at a hospital to cancel a FNA procedure. Thus, additional medically unnecessary FNA procedures are expected to occur with a clinical pathway for PCP to radiology compared to referrals from a PCP to a thyroid specialist.

To whatever extent the RVU reduction pushes a higher number of FNA to radiology providers, it will result in an increased number of medically unnecessary procedures.

### X. REDUCTION IN SPECIALIST WORKFORCE TRAINED TO PERFORM THE PROCEDURE

The RVU reduction has become common knowledge in endocrinology training programs, to the extent that fellows are often told that ultrasound guided FNA is a poor use of their time. FNA competence and expertise is increasingly absent as a fellowship training requirement by many fellowship programs.

The impact of reduced numbers of thyroid and endocrine specialists who are fully capable of performing FNA in their offices will result in acceleration of these problems, with reduced access and increased costs for many years to come.

Please note that we are not commenting on the associated codes that include Xray, CT, or MR imaging guidance, specifically codes 10007 through 10012. These are rarely performed by thyroid specialists and are primarily used at sites other than thyroid. (See attachment 4). The differences between each member of the CPT FNA" family" 10004 – 10021) would argue against lumping all of them together for RVU purposes, as they involve different specialties, different organs, and different disease types.

#### SUMMARY

The low valuation of the Fine Needle Aspiration RVU for CPT codes 10004, 10005, 10006 and 10021 has resulted in increased overall costs, reduced access, and reduced quality of care. We are seeing damage to the physician workforce capable of competently diagnosing and performing this procedure, which will further reduce access and increase costs for the foreseeable future.

The underpinnings of the reduction in RVU were flawed. The RVU crosswalk CPT code chosen by CMS is not comparable to Fine Needle Aspiration in any respect other than service time. There was absolutely no similarity in the amount of provider training, procedure risk and intensity, or patient population, and it is almost never billed to Medicare. The physician work previously associated with the imaging component appears to have been ignored.

From an RVU perspective, the Fine Needle Aspiration codes are not really a 'family', other than a fine needle is required somewhere. They involve different organs, for different reasons, different age groups, require different clinical training and experience, and are predominantly performed by different specialties.

Thyroid fine needle aspiration should be an outpatient procedure. There is absolutely no reason for it to require a hospital. Needlessly pushing ultrasound guided FNA into the inconvenient, high-cost, hazardous scenario of the hospitals should be rejected as nonsense.

CMS must act quickly to repair this problem to avoid further expense and reductions in quality.

#### CONCLUSION

We respectfully request that CMS consider the CPT codes 10004, 10005, 10006, and 10021 to be misvalued, and restore the work RVU to the values recommended by the AMA RUC.

We hope that you will share our serious concerns about reduced access, increased costs, and depletion of the provider talent pool willing to perform FNA procedures. Left unresolved, this problem will intensify, and we ask for prompt intervention by CMS to correct this in the CY2025 Physician Fee Schedule. This action would be harmonized with CMS stated goals

of improving access to care and reducing overall cost to the healthcare system. This would also help in maintaining a larger pool of clinical expertise to competently serve Medicare patients.

Unless corrected, we expect an extinction event for outpatient non-facility fine needle aspiration within the next few years, with a permanently high total cost of the procedure.

AACE, ATA and the members of the two organizations are committed to providing the highest quality care for our patients and the communities we serve. We are available for any further discussion or fact-finding should this be necessary. If you have any questions, please contact William Biggs, MD, FACE, at <u>william@amarilloaco.com</u>.

Sincerely,

Susat

Susan L. Samson, MD, PhD, FRCPC, FACE

President, AACE

ssamson@aace.com



Michael McDermott, MD

muchael ma Demost

President, ATA



Elevating the practice of clinical endocrinology to improve global health

#### ATTACHMENTS:

- 1 Table 12 with 2022 Claims Data and CMS adopted RVU
- 2 Table 12 with 2022 Claims Data and AMA proposed RVU
- 3 Translation table for procedure codes from 2018 to 2022
- 4 Comparison of CPT FNA family by imaging modality
- 5 Results of FNA provider survey by ATA and AACE

#### "TABLE 12" - REVISED FOR ACTUAL 2022 CLAIMS USING CMS ADOPTED RVU

HCPCS CODE	Utilization Source	Utilization Destination	Work RVU Source	Work RVU Destination	Work Pool Source	Work Pool Destination	Work Pool RVU Change	Work Pool % Change
10021 FNA no image	11,597	11339	1.27	1.00	14,728	11,339	(3,389)	
10004 2nd lesion		258		0.80	-	206	206	
10005 FNA US Imaging		127911		1.46	-	186,750	186,750	
76942 US Imaging	127,911		0.67	0.00	85,700	-	(85,700)	
10006 2nd lesion		30128		1.00		30,128	30,128	
10007 FNA Fluoro Imaging		660		1.81		1,195	1,195	
10008 2nd lesion		20		1.18		24	24	
77002 Needle localization by xray	660	)	0.54		356	-	(356)	
10009 FNA CT Imaging		2223		2.26		5,024	5,024	
10010 2nd lesion		29		1.65		48	48	
77012 Ct scan for needle biopsy	2223	3	1.16		2,579	-	(2,579)	
10011 FNA MRI Imaging		72		С		-	-	
10012 2nd lesion		49		С		-	-	
77021 Mr guidance for needle place	72	2	1.5		108	-	(108)	
10022 FNA with imaging	161,092		1.27	0.00	204,587	-	(204,587)	
TOTAL					308,058	234,713	(73,345)	-23.8%

#### "TABLE 12" - REVISED FOR ACTUAL 2022 CLAIMS USING AMA RUC RECOMMENDED RVU

HCPCS CODE	Utilization Source	Utilization Destination	Work RVU Source	Work RVU Destination	Work Pool Source	Work Pool Destination	Work Pool RVU Change	Work Pool % Change
10021 FNA no image	11,597	11339	1.27	1.20	14,728	13,607	(1,121)	
10004 2nd lesion		258		0.80	-	206	206	
10005 FNA US Imaging		127911		1.63	-	208,495	208,495	
76942 US Imaging	127,911		0.67	0.00	85,700	-	(85,700)	
10006 2nd lesion		30128		1.00		30,128	30,128	
10007 FNA Fluoro Imaging		660		1.81		1,195	1,195	
10008 2nd lesion		20		1.18		24	24	
77002 Needle localization by xray	660	)	0.54		356	-	(356)	
10009 FNA CT Imaging		2223		2.43		5,402	5,402	
10010 2nd lesion		29		1.65		48	48	
77012 Ct scan for needle biopsy	2223	5	1.16		2,579	-	(2,579)	
10011 FNA MRI Imaging		72		C		-	-	
10012 2nd lesion		49		C		-	-	
77021 Mr guidance for needle place	72	2	1.5		108	-	(108)	
10022 FNA with imaging	161,092		1.27	0.00	204,587	-	(204,587)	
TOTAL					308,058	259,104	(48,954)	-15.9%

#### Translation sheet for Source and Destination Claims Data

Translation sheet	: for Source and D	Destination Claims Data									
2022 CPT Code	2018 CPT Codes	Description	Equivalent 2018 CPT	Codes	2022 Claims	Equivalent 2	018 Claims	;			
10021		Fna bx w/o img gdn 1st les	10021		11,339	10021 11,597	10022	76942	77002	77012	77021
10004		Fna bx w/o img gdn ea addl	10021		258						
10005		Fna bx w/us gdn 1st les	10022 and 76942		127,911						
10006		Fna bx w/us gdn ea addl	10022		30,128						
	76942	Echo guide for biopsy					158,039	127,911			
10007		Fna bx w/fluor gdn 1st les	10022 and 77002		660		680		660		
10008		Fna bx w/fluor gdn ea addl	10022		20						
	77002	Needle localization by xray									
10009		Fna bx w/ct gdn 1st les	10022 and 77012		2223		2,252			2,223	
10010		Fna bx w/ct gdn ea addl	10022		29						
	77012	Ct scan for needle biopsy									
10011		Fna bx w/mr gdn 1st les	10022 and 77021		72		121				72
10012		Fna bx w/mr gdn ea addl	10022		49						
	77021	Mr guidance for needle place									
TOTAL					172,689	11,597	161,092	127,911	660	2,223	72

#### COMPARISON OF FNA BY IMAGING MODALITY

	2022 Claims		All-Site Speciality	Non-Facility Speciality	Top Diagnosis
	All Sites	Non-Facility			
10005 FNA Ultrasound	127,911	55,758	Radiology	Endocrinology	Thyroid nodule
10006 2nd lesion	30,128	15,068			
			_		
10007 FNA Fluoro	660	588	Surgery	Surgery	Osteoarthritis of the Knee
10008 2nd lesion	20	17			
10009 FNA CT imaging	2,223	125	Radiology	Radiology	Lung lesion
10010 2nd lesion	29	1			
10011 FNA MRI	72	64	Urology	Urology	Not available
10012 2nd lesion	49	42			
10021 FNA w/o imaging	11,339	7,776	ENT	ENT	Thyroid or neck mass
10004 2nd lesion	258	166			

#### Q1 Please describe in which system or setting you predominantly practice. Select all that apply



ANSWER CHOICES	RESPONSES	
Academic system	28.38%	21
Government system (e.g.VA)	8.11%	6
Community hospital or hospital system as employed practitioner	22.97%	17
Private Practice	45.95%	34
Other (please specify)	1.35%	1
Total Respondents: 74		
# OTHER (PLEASE SPECIFY)	DATE	

1

Employed in multispecialty group

9/27/2023 5:32 PM

## Q2 Do you have teaching responsibilities for residents and/or fellows in thyroid procedures (thyroid FNA and/or thyroid ultrasound)?



ANSWER CHOICES	RESPONSES	
Yes, I have teaching responsibilities	41.89%	31
No, I do NOT have teaching responsibilities	58.11%	43
TOTAL		74

### Q3 Please describe in which setting you predominantly practice. Select all that apply



ANSWER CHOICES	RESPONSES	
Practice serving predominantly rural population	6.76%	5
Practice serving predominantly urban and/or suburban population	82.43%	61
Practice serving predominantly affluent, insured population	36.49%	27
Practice serving predominantly disadvantaged or uninsured population	12.16%	9
Practice setting fee for service/ Out of Network/cash based	6.76%	5
Total Respondents: 74		

## Q4 How many years have you been in practice since completion of fellowship training?



ANSWER CHOICES	RESPONSES	
I am a fellow in training	6.76%	5
<5 years	18.92%	14
5-10 years	16.22%	12
11-20 years	32.43%	24
>20 years	25.68%	19
TOTAL		74

Q5 Do you think that the American Medical Association/Specialty Society Relative Value Scale Update Committee (RUC) should revalue CPT codes 10005 and 10006? (codes for thyroid FNA with ultrasound guidance)



ANSWER CHOICES	RESPONSES	
Yes	89.19%	66
No	0.00%	0
Not Sure	10.81%	8
TOTAL		74

## Q6 Has the number of FNA procedures you perform in practice changed since the decrease in valuation of FNA by CMS in 2019?



ANSWER CHOICES	RESPONSES	
No change	41.89%	31
Increased	10.81%	8
Decreased	29.73%	22
Not applicable; I did not practice prior to 2019	20.27%	15

Total Respondents: 74

#	IF THE NUMBER HAS INCREASED OR DECREASED, ESTIMATE THE % CHANGED	DATE
1	Down 20% - due to unrelated practice changes	10/4/2023 8:08 PM
2	2%	10/4/2023 9:27 AM
3	20%	10/3/2023 2:41 PM
4	30	10/3/2023 7:27 AM
5	50% down	10/3/2023 12:21 AM
6	30%	10/2/2023 2:44 PM
7	10	10/2/2023 2:31 PM
8	20	9/29/2023 6:29 AM
9	33%	9/28/2023 10:13 PM
10	50-75%	9/28/2023 4:31 PM

#### FNA Reimbursement Survey

11	30%	9/28/2023 2:58 AM
12	10	9/27/2023 9:08 PM
13	50	9/27/2023 7:03 PM
14	50	9/27/2023 4:06 PM
15	30	9/27/2023 11:48 AM
16	I no longer perform FNA because of reimbursement starting 2023	9/27/2023 10:22 AM
17	10%	9/27/2023 9:45 AM
18	50-75%	9/21/2023 4:00 PM
19	50%	9/21/2023 10:58 AM

#### Q7 If you DO NOT perform FNAs, please describe to whom you refer FNAs. Select all that apply



ANSWER CHOICES RESPONSES		
Another endocrinologist	12.00%	3
Physician assistant/nurse practitioner	0.00%	0
Radiologist	72.00%	18
Surgeon	4.00%	1
Pathologist	12.00%	3
Other (please specify)	12.00%	3
Total Respondents: 25		

#	OTHER (PLEASE SPECIFY)	DATE
1	Na	10/1/2023 7:44 AM
2	n/a	9/27/2023 5:32 PM
3	radiology at hospital which is usually a PA with minimal experience	9/21/2023 4:00 PM

# Q8 Please indicate how you think patient outcomes may have been affected by the change in FNA valuation by CMS in 2019. Select all that apply



ANSWER CHOICES	RESPON	SES
Patients increasingly need to make additional appointments with outside providers or facilities which leads to inconvenience and/or expense	67.61%	48
It has become more challenging to find these services for my patient	22.54%	16
Communication between treating physician and patient is reduced	26.76%	19
Patients experience the inconvenience of having a procedure with different staff or location of service	57.75%	41
Patient outcomes have not been affected	7.04%	5
I am not sure whether patient outcomes have been affected, negatively or positively	23.94%	17
Other (please specify)	14.08%	10
Total Respondents: 71		

#	OTHER (PLEASE SPECIFY)	DATE
1	Patients sometimes need to have 2 procedures as the centers performing them are not keeping up with the evidence based care or do not have that opportunity.	10/12/2023 12:01 AM
2	I was not aware of the change. Perhaps ask radiology. Our practice refers to radiology because our institution decided this, as the fee is higher in the radiology/hospital setting. It works well for us, though.	10/6/2023 3:39 PM

#### FNA Reimbursement Survey

3	Physician well-being has been impacted, and the valuation is ridiculously low.	10/6/2023 12:03 AM
4	I do FNAs but will only do 1/2 day per month as a 1/2 day of FNA give me far fewer RVUs that a 1/2 day of clinic. Beyond the # I can do in that clinic I refer to other providers.	10/2/2023 2:31 PM
5	Main issue is insurances (some) not covering ultrasound and fna on same day.	9/28/2023 2:40 AM
6	It takes much longer for patients to get FNA done due to scheduling	9/27/2023 9:08 PM
7	multiple appointments for office visit and procedure, patient inconvenience and difficulty with scheduling	9/27/2023 5:32 PM
8	Eventually this will cost everyone more because as i can't afford to do this anymore, pts needs multiple appts, 1 with me then IR or radiologist. the IR or Radiologists are more costly. then follow up with me if biopsy is abnormal. i used to perform all consults and biopsy's same day to make is more convenient for the patient but now i don't ever do that as i need to move to another patient faster and faster each year to just stay afloat	9/27/2023 11:48 AM
9	i am just doing the FNAs regardless of the reimbursement so patient care is not affected	9/27/2023 11:34 AM
10	Radiologist do not understand the usage of molecular studies which lead to unnecessary surgeries or repeated FNA. The cost is more for patients.	9/27/2023 10:22 AM

Q9 If you DO perform FNAs, please describe the time you typically spend with a patient (i.e., discussion of procedure, consent, preparation for procedure, patient positioning, ultrasound guidance, procedure, postprocedure patient monitoring and clean-up).



ANSWER CHOICES	RESPONSES	
< 20 minutes	13.64%	9
21-30 minutes	36.36%	24
31-40 minutes	28.79%	19
> 40 minutes	21.21%	14
TOTAL		66

### Q10 If you DO NOT perform FNAs, please SELECT factors that led to this decision. Select all the apply



ANSWER C	HOICES		RESPON	SES
	performing FNA is not as well reimbursed as seeing a patient in consultation or follow-up (less value r visits seen in similar time)	e than	52.94%	9
Overhead ex	pense (sonographer, ultrasound equipment, room charges, prior authorization cost)		58.82%	10
Other barrier	s (please specify)		41.18%	7
Total Respo	ndents: 17			
#	OTHER BARRIERS (PLEASE SPECIFY)	DATE		
1	Hospital can charge higher fee/hospital fee.	10/6/202	3 3:39 PM	
2	Not routine belt done by physician	10/4/202	3 9:27 AM	
3	I didn't like any intervention.	9/29/202	23 3:54 AM	
4	I don't like doing them	9/27/202	3 10:36 PM	
5	Not extremely interested in doing FNAs/don't feel I have enough experience to expertly perform them.	9/27/202	3 8:10 PM	
6	Not interested in performing procedures	9/27/202	3 7:12 PM	
7	Not covered by some plans if done in office	9/27/202	3 7:03 PM	